In 139 efficacy-evaluable patients with CLL/SLL, the ORR was 63% (95% CI, 55–71%); in 121 efficacy-evaluable patients previously treated with BTK inhibitors, the ORR was 62% (95% CI, 53–71%). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.